Drugs / Flanax 550mg
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04384367 Comparator | Dec 2022 → Oct 2024 | migraine disorder | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flanax 550mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04384367 ↗ |
| Route | Oral | “oral - single dose” NCT04384367 ↗ |